He posts this: "Orbimed Advisors added 3.6 million shares of Sequenom to its books in the second quarter, while Sectoral Asset Management acquired just under 1 million shares. Millennium Management was also a buyer.
Sellers of Sequenom included SAC Capital (2.1 million shares) and RedMile Group (1 million shares), although both firms retain significant positions. Other sellers included APEX Capital and CR Intrinsic Investors, which is also connected to Cohen's SAC Capital "
After that he is made aware that he failed to mention a 12 million share add by FMR in Q2.
His reply: "the article focuses on hedge fund buying and selling in the second quarter. no need for a correction"
Reply to Adam Feuerstein: "Fidelity not hedge funds thus need not mention 12mln add->shows sell side bias imo. Especially since the 12 million add pales the buy and sell side 1mln, 2mln buys/sells by active trade hedgies. And the 19 million short position will be MUCH harder to cover with the 12 mln taken out of the float. "
With some 19 million shorts SQNM will likely see put selling, call buying, actual long buying and covering after that. Will inevitably run up towards end of year.
Company still projects late 2011/early 2012 for completion and approval of T21 test and commercial start (non invasive DOw test, massively superior to current tests AND non invasive (ie no added chance to loose your baby by doing the test))
SQNM Catalyst is T21 test (Dow testy) , end of year/early 2012 completed and commercialization as well.
That only 3-5 months out with 70% inst interest and 20% short..... interesting.
So both catalyst AND a small float. And past highs based on the same T21 test that was withdrawn from FDA due to employee mishanding of the data.(results were very positive at the time but might have had employee interference, company stated at the time YES there had been interference but results would be same and stated to redo the trials)
2010/2011 used to redo the trials... and ready now soon.
SO i think good play for longer swing here 2-6 months
Thank you for providing clarity. Apropos the timing element of a pending FDA approval.....is it appropriate to suggest that there has to be "some" amount of pressure on the FDA for getting mC approved...if only for the purpose of helping relieve some of the financial pressure/cost associated with purchasing the Teva Branded Copaxone? With TEVA's price increases these last few years, patients have to be really feeling a pinch.
News 
Market Data 
Discover 
AI
